ADVM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADVM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Adverum Biotechnologies's Total Long-Term Assets for the quarter that ended in Sep. 2024 was $73.30 Mil.
The historical data trend for Adverum Biotechnologies's Total Long-Term Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adverum Biotechnologies Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Long-Term Assets | Get a 7-Day Free Trial | 46.86 | 48.13 | 122.58 | 117.78 | 70.24 |
Adverum Biotechnologies Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Total Long-Term Assets | Get a 7-Day Free Trial | 72.17 | 70.24 | 68.70 | 74.39 | 73.30 |
Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.
Thank you for viewing the detailed overview of Adverum Biotechnologies's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Lupher, Jr. Mark L. | director | C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025 |
James Paul Scopa | director | 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
C. David Nicholson, | director | 103 CHILDS ROAD, BASKIN RIDGE NJ 07092 |
Setareh Seyedkazemi | officer: Chief Development Officer | C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL DRIVE, REDWOOD CITY CA 94063 |
Linda M Rubinstein | officer: Chief Financial Officer | 25861 INDUSTRIAL BLVD, HAYWARD CA 94545 |
Peter Soparkar | officer: Chief Legal Officer | C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063 |
Brigit Riley | officer: Chief Scientific Officer | 100 CARDINAL WAY, REDWOOD CITY CA 94063 |
Laurent Fischer | director, officer: CEO and Director | C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063 |
Richard Beckman | officer: Chief Medical Officer | C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063 |
Nancy E Pecota | officer: Principal Accounting Officer | ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545 |
John Rakow | officer: SVP, Genl Counsel, Acting CFO | C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063 |
Rupert D'souza | officer: Chief Financial Officer | C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063 |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Soo Hong | director | C/O ADVERUM BIOTECHNOLOGIES, INC., 800 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Rabia Gurses Ozden | director | C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210 |
From GuruFocus
By Marketwired • 05-03-2024
By Marketwired • 08-12-2024
By GuruFocus News • 11-15-2024
By Marketwired • 11-04-2024
By Marketwired • 10-16-2024
By GuruFocus News • 11-13-2024
By GuruFocus Research • 03-20-2024
By Marketwired • 11-18-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.